Itanapraced

Itanapraced (CHF5074) is an orally active γ-secretase modulator and a non-steroidal anti-inflammatory derivative. Itanapraced reduces Aβ42 and Aβ40 secretion with IC50 values of 3.6 and 18.4 μM, respectively. Itanapraced inhibits cell apoptosis of hippocampal neurons induced by oxygen and glucose deprivation (OGD) . Itanapraced can be used for the research of Alzheimer's disease[1][2].

Product Specifications

CAS Number

[749269-83-8]

Product Name Alternative

CHF5074; CSP-1103

UNSPSC

12352005

Hazard Statement

H302, H315, H320, H335

Target

Apoptosis; γ-secretase

Type

Reference compound

Related Pathways

Apoptosis; Neuronal Signaling; Stem Cell/Wnt

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/CHF5074.html

Concentration

10mM

Purity

99.37

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

OC(C1(CC1)C(C=C2)=CC(F)=C2C3=CC=C(Cl)C(Cl)=C3)=O

Molecular Formula

C16H11Cl2FO2

Molecular Weight

325.16

Precautions

H302, H315, H320, H335

References & Citations

[1]Imbimbo BP, et al. 1- (3',4'-Dichloro-2-fluoro[1,1'-biphenyl]-4-yl) -cyclopropanecarboxylic acid (CHF5074), a novel gamma-secretasemodulator, reduces brain beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease withoutcausing peripheral toxicity. J Pharmacol Exp Ther. 2007 Dec;323 (3) :822-830.|[2]Mango D, et al. Electrophysiological and metabolic effects of CHF5074 in the hippocampus: protection against in vitro ischemia. Pharmacol Res. 2014 Mar;81:83-90.